MedTrace Logo

Exosome Injection Versus Topical Minoxidil for Androgenetic Alopecia

NCT07776015 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-08-20

No results posted yet for this study

Summary

Androgenetic alopecia (AGA) is a common form of hair loss characterized by progressive hair follicle miniaturization. This prospective randomized comparative study evaluates the efficacy and safety of intradermal exosome injections compared with 5% topical minoxidil in patients with AGA. Forty patients were randomly assigned to receive either intradermal exosome injections or topical minoxidil for three months, with clinical, trichoscopic, patient-reported, and safety outcomes assessed at baseline, after treatment, and at 3-month follow-up.

Conditions

Interventions

OTHER

exosomes injection

intradermal injections of 1 mL of Exomide

DRUG

Topical Minoxidil 5%

5% topical minoxidil solution

Sponsors & Collaborators

  • Tanta University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-20
Primary Completion
2024-05-30
Completion
2025-12-31

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07776015 on ClinicalTrials.gov